Mind Competitors

Delisted . USA . 
Stock . Mind Medicine
MNMDDelisted Stock  USD 15.38  0.27  1.79%   
Mind Medicine competes with UroGen Pharma, BridgeBio Oncology, Tango Therapeutics, AnaptysBio, and Rezolute; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Mind Medicine competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Mind Medicine to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Mind Medicine vs Savara Correlation

Very good diversification

The correlation between Mind Medicine and SVRA is -0.35 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Mind Medicine and SVRA in the same portfolio, assuming nothing else is changed.

Moving against Mind Stock

  0.65HPQ HP IncPairCorr
  0.42UIS UnisysPairCorr
  0.39ORGN Origin Materials Earnings Call This WeekPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
12.3015.6619.02
Details
Intrinsic
Valuation
LowRealHigh
8.7712.1315.49
Details

Mind Medicine Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mind Medicine and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Mind and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mind Medicine does not affect the price movement of the other competitor.

High positive correlations

SVRA
+ 0.9
NRIX
KOD
+ 0.88
FTRE
KOD
+ 0.86
NRIX
FTRE
+ 0.8
NRIX
FTRE
+ 0.77
ANAB
SVRA
+ 0.77
FTRE
  

High negative correlations

FTRE
- 0.83
RZLT
RZLT
- 0.77
ANAB
KOD
- 0.7
RZLT
XNCR
- 0.61
TNGX
SVRA
- 0.58
RZLT
NRIX
- 0.58
RZLT

Risk-Adjusted Indicators

There is a big difference between Mind Stock performing well and Mind Medicine Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mind Medicine's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
URGN  2.95 (0.18) 0.00 (0.11) 0.00 
 0.00 
 5.71 
(5.50)
 21.64 
BBOT  3.62  0.03  0.00  0.14  4.11 
(4.52)
 9.92 
(7.04)
 31.80 
TNGX  3.74  0.79  0.19  2.84  3.28 
(4.64)
 11.29 
(5.65)
 31.20 
ANAB  2.71  0.66  0.12 (1.89) 3.60 
(2.89)
 6.60 
(5.53)
 18.10 
RZLT  7.19  0.84  0.03 (0.14) 15.06 
(8.16)
 18.05 
(9.22)
 99.29 
XNCR  2.83 (0.16) 0.00 (0.59) 0.00 
 0.00 
 6.72 
(5.08)
 16.84 
NRIX  3.18  0.41  0.11  0.69  3.11 
(3.96)
 7.07 
(5.37)
 27.63 
FTRE  3.44 (0.11) 0.02  0.06  4.80 
(3.86)
 7.52 
(8.13)
 28.43 
KOD  4.12  0.41  0.11  0.32  4.01 
(4.53)
 9.66 
(6.87)
 23.68 
SVRA  3.10  0.47  0.12  4.65  3.11 
(3.90)
 8.25 
(5.30)
 24.50 

Mind Medicine Competitive Analysis

The better you understand Mind Medicine competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mind Medicine's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mind Medicine's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MNMD URGN BBOT TNGX ANAB RZLT XNCR NRIX FTRE KOD
 1.79 
 15.38 
Mind
 2.45 
 21.14 
UroGen
 11.07 
 12.04 
BridgeBio
 1.35 
 12.44 
Tango
 9.97 
 55.25 
AnaptysBio
 9.77 
 3.37 
Rezolute
 5.81 
 11.51 
Xencor
 2.07 
 16.11 
Nurix
 18.72 
 9.42 
Fortrea
 1.76 
 22.91 
Kodiak
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Not too volatile
Slightly risky
Somewhat reliable
Very steady
Dangerous
Not too volatile
Not too volatile
Somewhat reliable
Not too volatile
Market Performance
(90 Days Performance)
Solid
Weakest
Weakest
Good
Solid
Weak
Weakest
Fair
Mild
Mild
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
High
High
Low
Small
High
Small
Low
Moderate
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Hold
Hold
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Hold
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Hold
Current Ratio
13.86
7.74
N/A
9.76
22.79
61.78
7.81
5.26
N/A
8.65
Net Asset
302.15 M
285.71 M
194.42 M
316.49 M
483.83 M
175.49 M
951.95 M
688.13 M
3.58 B
335.58 M
Profit Margin
N/A
-1.71
N/A
-1.51
-0.5
N/A
-0.87
N/A
-0.37
N/A
EBITDA
(105.87 M)
(95.35 M)
(80.66 M)
(143.1 M)
(92.74 M)
(79.86 M)
(186.17 M)
(244.84 M)
(64.3 M)
(149.5 M)
Current Valuation
1.3 B
1.02 B
856.64 M
1.59 B
1.16 B
140.89 M
470.86 M
1.18 B
2.43 B
1.41 B
Price To Book
11.22
19.27
N/A
10.84
114.73
1.98
1.4
3.19
2.37
60.09
Operating Margin
N/A
-1.0
N/A
0.26
0.45
N/A
-2.26
-6.12
-0.0053
N/A
Retained Earnings
(398.88 M)
(806.22 M)
(3.73 M)
(501.56 M)
(759.33 M)
(403.86 M)
(704.04 M)
(1 B)
(397 M)
(1.33 B)
Current Asset
N/A
N/A
N/A
N/A
297.84 M
N/A
97.67 M
N/A
N/A
7.31 M
Beta
2.62
1.36
N/A
1.76
0.35
0.51
0.97
1.97
1.57
2.65
Number Of Employees
74
287
81
155
136
75
250
317
14.5 K
123
Shares Outstanding
97.22 M
46.81 M
79.2 M
134.68 M
27.69 M
92.73 M
71.41 M
102.84 M
92.4 M
61.05 M
Cash Flow From Operations
(79.13 M)
(96.77 M)
(763.82 K)
(131.5 M)
(135.34 M)
(69.08 M)
(202.19 M)
(249.47 M)
262.8 M
(117.32 M)
Total Debt
21.85 M
123.39 M
5.71 M
36.49 M
369.46 M
1.61 M
231.95 M
55.73 M
1.2 B
70.34 M
Return On Equity
-0.86
-14.81
N/A
-0.52
-3.08
-0.59
-0.2
-0.5
-0.98
-2.08
Return On Asset
-0.34
-0.34
N/A
-0.25
-0.0423
-0.37
-0.0909
-0.26
-0.0132
-0.47
Number Of Shares Shorted
15.05 M
10.3 M
2.16 M
45.82 M
5.57 M
18.98 M
10.92 M
14.96 M
9.22 M
7.32 M
Book Value Per Share
1.7
-2.47
-403.34
1.43
-1.07
1.62
8.77
5.29
6.3
0.45
Current Liabilities
N/A
N/A
N/A
N/A
16.6 M
N/A
43.43 M
N/A
N/A
4.89 M
Total Asset
302.15 M
285.71 M
194.42 M
316.49 M
483.83 M
175.49 M
951.95 M
688.13 M
3.58 B
335.58 M
Short Ratio
7.82
14.16
2.07
14.1
11.67
2.3
15.08
11.39
7.47
6.39
Target Price
28.67
35.25
24.2
15.25
67.92
4.25
28.83
30.0
16.44
30.71
Debt To Equity
N/A
0.44
N/A
0.002
0.066
0.001
0.056
0.038
N/A
0.16
Shares Owned By Institutions
41.64
99.6
51.02
99.96
93.97
89.49
98.76
85.87
99.45
80.06
Market Capitalization
1.45 B
1.01 B
1.01 B
1.71 B
1.41 B
284.67 M
872.64 M
1.69 B
1.26 B
1.42 B
Price To Earning
N/A
239.57
N/A
N/A
81.21
N/A
69.81
N/A
N/A
-2.29
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.01
-0.08
Price To Sales
N/A
10.51
N/A
25.7
8.29
N/A
5.81
20.14
0.46
N/A
Net Income
(108.68 M)
(126.87 M)
7.6 M
(130.3 M)
(145.23 M)
(74.41 M)
(236.54 M)
(264.46 M)
(271.5 M)
(176.21 M)
Earnings Per Share
-1.98
-3.47
-1.11
-0.91
-2.82
-0.92
-1.71
-3.05
-11.35
-3.95
Shares Owned By Insiders
0.59
3.8
24.04
4.98
6.03
10.51
1.24
1.12
0.55
4.77
Revenue
N/A
90.4 M
N/A
42.07 M
91.28 M
N/A
110.49 M
83.98 M
2.7 B
N/A
Working Capital
242.77 M
230.19 M
139.11 M
228.17 M
386.45 M
159.23 M
490.17 M
520.35 M
(1.3 M)
146.36 M
Cash And Equivalents
105.74 M
111.74 M
N/A
416.36 M
442.15 M
150.41 M
511.92 M
344.48 M
N/A
597.88 M
Cash Per Share
3.71
4.91
N/A
4.73
15.66
3.87
8.57
7.31
N/A
11.55
Gross Profit
N/A
84.89 M
N/A
(67.5 M)
16.47 M
N/A
(75.53 M)
(232.92 M)
513.6 M
N/A
Day Typical Price
15.21
21.15
11.57
12.44
52.83
3.28
11.51
16.11
9.42
22.64
Accumulation Distribution
0.0478
51583.16
44045.05
N/A
215289.0
846249.0
N/A
36620.34
N/A
40095.89
Market Facilitation Index
0.74
0.0
0.0
N/A
0.0
N/A
N/A
0.0
N/A
0.0
Daily Balance Of Power
0.3649
(0.28)
0.7186
0
0.5252
0.5263
0
(0.40)
0
(0.33)
Period Momentum Indicator
0.27
(0.53)
1.2
(0.17)
5.01
0.3
(0.71)
(0.34)
(2.17)
(0.41)
Rate Of Daily Change
1.02
0.98
1.11
0.99
1.1
1.1
0.94
0.98
0.81
0.98
Day Median Price
15.12
21.16
11.34
12.44
51.62
3.24
11.51
16.11
9.42
22.5
Price Action Indicator
0.4
(0.29)
1.3
(0.09)
6.13
0.29
(0.36)
(0.17)
(1.08)
0.21
Coefficient Of Variation
967.61
(4,544)
5178.33
655.5
612.13
2615.34
(2,738)
939.66
2492.96
862.69
Mean Deviation
3.07
2.95
3.62
3.74
2.71
7.19
2.83
3.18
3.44
4.12
Jensen Alpha
0.3681
(0.18)
0.0308
0.7902
0.6574
0.8434
(0.16)
0.4057
(0.11)
0.406
Total Risk Alpha
(0.07)
(0.56)
(0.51)
0.1782
0.1674
(1.10)
(0.57)
(0.06)
(0.39)
(0.02)
Sortino Ratio
0.0851
N/A
(0)
0.1898
0.1234
0.0258
N/A
0.1084
0.0188
0.1081
Downside Variance
14.75
N/A
17.46
14.54
18.66
263.0
N/A
12.0
24.7
19.96
Standard Deviation
4.16
3.91
5.08
5.42
3.9
13.64
3.6
4.5
4.91
5.06
Kurtosis
2.49
1.78
2.53
4.09
3.02
26.46
(0.02)
3.76
2.18
(0.31)
Potential Upside
6.21
5.71
9.92
11.29
6.6
18.05
6.72
7.07
7.52
9.66
Treynor Ratio
0.7537
(0.11)
0.1436
2.84
(1.89)
(0.14)
(0.59)
0.6911
0.0597
0.3159
Maximum Drawdown
28.06
21.64
31.8
31.2
18.1
99.29
16.84
27.63
28.43
23.68
Variance
17.32
15.25
25.82
29.39
15.18
186.01
12.96
20.26
24.06
25.59
Market Risk Adjusted Performance
0.7637
(0.10)
0.1536
2.85
(1.88)
(0.13)
(0.58)
0.7011
0.0697
0.3259
Risk Adjusted Performance
0.09
(0.01)
0.0237
0.1295
0.1374
0.0397
(0.02)
0.0926
0.0402
0.1003
Skewness
0.2237
(0.75)
0.8167
1.52
(0.66)
(3.86)
0.3337
1.22
(0.38)
0.307
Semi Deviation
3.4
N/A
4.11
3.28
3.6
15.06
N/A
3.11
4.8
4.01
Information Ratio
0.0785
(0.05)
(0)
0.1335
0.1368
0.0307
(0.07)
0.0835
0.019
0.0955
Value At Risk
(4.21)
(5.50)
(7.04)
(5.65)
(5.53)
(9.22)
(5.08)
(5.37)
(8.13)
(6.87)
Expected Short fall
(3.39)
N/A
(4.52)
(4.64)
(2.89)
(8.16)
N/A
(3.96)
(3.86)
(4.53)
Downside Deviation
3.84
N/A
4.18
3.81
4.32
16.22
N/A
3.46
4.97
4.47
Semi Variance
11.53
N/A
16.9
10.77
12.95
226.94
N/A
9.68
23.05
16.04

Mind Medicine Competition Performance Charts

Five steps to successful analysis of Mind Medicine Competition

Mind Medicine's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mind Medicine in relation to its competition. Mind Medicine's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Mind Medicine in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mind Medicine's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mind Medicine, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Mind Medicine position

In addition to having Mind Medicine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Sports Thematic Idea Now

Sports
Sports Theme
Companies in sporting activities arena as well as manufacturers of sporting goods and sport retailers. The Sports theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sports Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Other Consideration for investing in Mind Stock

If you are still planning to invest in Mind Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mind Medicine's history and understand the potential risks before investing.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Money Managers
Screen money managers from public funds and ETFs managed around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY